Quebec-based Ortho Regenerative Technologies closed a non-brokered private placement of units. The company issued 7.7 million units at a purchase price of $0.32 per unit for total gross proceeds of $2.47 million.
The net proceeds will fund ongoing value creation activities including:
securing FDA approval to start U.S. clinical trials for the ORTHO-R rotator cuff repair
manufacturing GMP clinical trial batch for ORTHO-R
completing U.S. clinical trial investigation sites, setting and training
starting U.S. clinical trial patient enrollment activities
securing U.S. exchange listing for company shares
ongoing general and administrative corporate operations
Claude LeDuc, Chief Executive Officer of Ortho Regenerative Technologies, said, “These are very exciting times for the Company as we get ready to proceed with the U.S. clinical portion of our Ortho-R development program. This financing enables us to complete key preparatory work initiatives and begin the U.S. clinical trial. We expect our progress to be reflected over the coming months with the delivery of anticipated catalysts and milestones.”
Quebec-based Ortho Regenerative Technologies closed a non-brokered private placement of units. The company issued 7.7 million units at a purchase price of $0.32 per unit for total gross proceeds of $2.47 million.
The net proceeds will fund ongoing value creation activities including:
securing FDA approval to start U.S. clinical...
Quebec-based Ortho Regenerative Technologies closed a non-brokered private placement of units. The company issued 7.7 million units at a purchase price of $0.32 per unit for total gross proceeds of $2.47 million.
The net proceeds will fund ongoing value creation activities including:
securing FDA approval to start U.S. clinical trials for the ORTHO-R rotator cuff repair
manufacturing GMP clinical trial batch for ORTHO-R
completing U.S. clinical trial investigation sites, setting and training
starting U.S. clinical trial patient enrollment activities
securing U.S. exchange listing for company shares
ongoing general and administrative corporate operations
Claude LeDuc, Chief Executive Officer of Ortho Regenerative Technologies, said, “These are very exciting times for the Company as we get ready to proceed with the U.S. clinical portion of our Ortho-R development program. This financing enables us to complete key preparatory work initiatives and begin the U.S. clinical trial. We expect our progress to be reflected over the coming months with the delivery of anticipated catalysts and milestones.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
